FindTrial
Sign In

Use of Probiotics in Treating Acute Gastroenteritis.

A cross-sectional study to assess the real world utilization and safety of Multistrain probiotic in Acute gastroenteritis in outpatient settings of India (MAESTRO Study) - MAESTRO

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061546
Enrollment
3905
Registered
2024-01-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K529- Noninfective gastroenteritis and colitis, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Torrent Pharmaceuticals Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with acute gastroenteritis and treated with multistrain probiotics for 7 days

Exclusion criteria

Exclusion criteria: Contraindications to ingredients. Any other condition or factors as per discretion of treating physician.

Design outcomes

Primary

MeasureTime frame
Changes in stool frequency and consistency after probiotic administration.Timepoint: From baseline (Day-0) to Day-7—

Secondary

MeasureTime frame
Most common cause of acute gastroenteritis. Change in ORS requirement. Safety assessment. Dosage frequency for probiotics. Concomitant medications.Timepoint: From baseline (Day-0) to Day-7—

Countries

India

Contacts

Public ContactDr Rathish Nair PhD MBA

Torrent Pharmaceuticals Ltd

krishnaprasadkorukonda@torrentpharma.com7069000572

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026